GlassScriptPhysician profile
Misbah Zaheer
NPI 1942450267
$1,836.03
in general payments reported to CMS, 2019-2025
26 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $142 · 2022: $198 · 2023: $461 · 2024: $294 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $351.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.35 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $162.82 | 2019-2024 | Auryxia |
| Amgen INC. | $122.86 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $110.17 | 2022-2025 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $101.04 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $94.77 | 2020 | |
| Ardelyx, INC. | $92.80 | 2025 | Ibsrela |
| Travere Therapeutics, INC. | $77.19 | 2022-2024 | |
| Horizon Therapeutics Plc | $70.65 | 2019-2023 | Krystexxa, Tepezza |
| Ani Pharmaceuticals, INC. | $58.98 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $55.04 | 2023-2024 | Korsuva, Veltassa |
| Mallinckrodt Enterprises LLC | $40.54 | 2019 | |
| Calliditas Therapeutics US INC. | $38.84 | 2023 | Tarpeyo |
| Amarin Pharma, INC. | $30.29 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29.66 | 2022 | |
| Genzyme Corporation | $28.48 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $26.21 | 2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $21.13 | 2023 | |
| Scpharmaceuticals INC. | $20.69 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $18.21 | 2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $18.08 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.49 | 2023 | Gattex |
| Alnylam Pharmaceuticals INC. | $17.48 | 2024 | Givlaari |
| Biomerieux INC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misbah Zaheer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.